Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12794411 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TDP1USP2ALOX15CHRNB2 | |
| SCHEMBL14706726 | 0.88 | ALDH1A1 (0.54) | ALDH1A1TDP1USP2ALOX15CHRNB2 | |
| SCHEMBL9182928 | 0.88 | ALDH1A1 (0.40) | ALDH1A1TDP1USP2ALOX15CHRNB2 | |
| SCHEMBL17540730 | 0.86 | ALDH1A1 (0.60) | ALDH1A1TDP1USP2ALOX15CHRNB2 | |
| Chaulmoogric Acid SCHEMBL560850 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15HSD17B10 | |
| SCHEMBL4558351 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15HSD17B10 | |
| SCHEMBL580439 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15HSD17B10 | |
| SCHEMBL2491883 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15HSD17B10 | |
| SCHEMBL2494531 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15HSD17B10 | |
| Chaulmoogric Acid SCHEMBL560849 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TDP1USP2ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513235-B | Process for producing diglyceride | 帝斯曼知识产权资产管理有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-109010827-A | Chlorambucil-poly-dopamine prodrug nanoparticle antitumor application thereof | 上海交通大学 | 2018-12-18 | — | — | CN | disclosed |
| US-20100221809-A1 | Compositions and Methods for the Isolation of Biologically Active Proteins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-09-02 | — | — | US | disclosed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | disclosed |
| US-6008398-A | Non-nucleotide phosphorus ester oligomers | GENZYME CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| US-5919965-A | Non-nucleotide phosphorus ester oligomers | GENZYME CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0880532-A4 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0880532-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0804443-A4 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
| EP-0804443-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997028168-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
| WO-1996022297-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221809-A1 | Compositions and Methods for the Isolation of Biologically Active Proteins | PLA2G4C, PLA2G4A, PEBP1 | ALDH1A1 4847/4885TDP1 3102/4885USP2 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.